Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Inclusion Criteria

• •Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• •Age ≥ 18 years at the time of consent.
• •Eastern Cooperative Oncology Group (ECOG) performance status of = 2
• •Able to comply with the study protocol, in the investigator's judgment.
• •Histologically documented, locally advanced (T4b, any N; or any T, N 2-3) or metastatic urothelial carcinoma (mUC) (M1, Stage IV) (also termed TCC or UCC of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra) Patients with mixed histologies are required to have a dominant transitional cell pattern. Locally advanced bladder cancer must be inoperable on the basis of involvement of pelvic sidewall or adjacent viscera (clinical Stage T4b) or bulky nodal metastasis (N2-N3).
• •Measurable disease, as defined by RECIST v1.1
• •Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens (metastatic specimens preferable but if not available primary tumor specimens that are at least muscle-invasive are acceptable) in paraffin blocks (blocks preferred) or at least 15 unstained slides. If archival tissue is not available, subjects may be considered for enrollment on a case by case basis after discussion with the sponsor-investigator.
• •No prior chemotherapy for inoperable locally advanced or mUC. For patients who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval \> 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment naive in the metastatic setting.
• •Cisplatin-ineligible as defined by at least one of the following:
• •* Calculated creatinine clearance ≥ 30 (Cockroft-Gault)
• •* ECOG performance status of 2 or greater
• •* CTCAE v4 Grade ≥ 2 audiometric hearing loss
• •Demonstrate adequate organ function. All screening labs to be obtained within 28 days prior to registration:
• •* Hematological:
• •* Absolute Neutrophil Count (ANC) ≥ 1.5 x 10\^9/L
• •* Hemoglobin (Hgb) ≥ 9 g/dL
• •* Platelets ≥ 100 x 10\^9/L
• •* Renal:
• •• Calculated creatinine clearance ≥ 30 mL/min (Cockroft-Gault)
• •* Hepatic:
• •* Bilirubin ≤ 1.5 × upper limit of normal (ULN) (except subjects with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL)
• •* Aspartate aminotransferase (AST) ≤ 3 × ULN
• •* Alanine aminotransferase (ALT) ≤ 3 × ULN
• •Women of childbearing potential must have a negative serum or urine pregnancy.
• •Women of childbearing potential (WOCBP) and male subjects must use appropriate method(s) of contraception as stated for the timeline below. Male subjects are not required to use contraception as outlined in protocol.